Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

NCT03077451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Kaposi Sarcoma
Skin Kaposi Sarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Nelfinavir Mesylate

Sponsor

AIDS Malignancy Consortium

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]